| Code | CSB-RA850914MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to NGM-831, targeting LILRB4 (Leukocyte Immunoglobulin-Like Receptor B4), an inhibitory immune checkpoint receptor predominantly expressed on myeloid cells including monocytes, macrophages, and dendritic cells. LILRB4 functions as a critical regulator of immune responses by delivering inhibitory signals upon ligand binding, thereby suppressing myeloid cell activation and antigen presentation. This receptor plays a significant role in immune evasion mechanisms in various malignancies, particularly acute myeloid leukemia (AML), where it is frequently overexpressed on leukemic blasts and contributes to tumor immune escape by impairing anti-tumor immunity.
NGM-831 is an investigational therapeutic antibody designed to block LILRB4 function, thereby enhancing myeloid cell-mediated immune responses against cancer cells. This biosimilar provides researchers with a valuable tool for investigating LILRB4-mediated immunosuppression, studying myeloid checkpoint biology, and exploring therapeutic strategies targeting the tumor microenvironment. It supports studies in immuno-oncology, myeloid biology, and immune checkpoint regulation across hematologic and solid tumor models.
There are currently no reviews for this product.